{"article": [{"url": "https://www.marketwatch.com/story/spruce-biosciences-stock-opens-more-than-20-above-its-ipo-price-then-pulls-back-2020-10-09", "published": 1602244760.0, "headline": "Spruce Biosciences stock opens more than 20% above its IPO price, then pulls back", "body": "Shares of Spruce Biosciences Inc. SPRB, +13.33% rallied in their public debut, as they opened 21% above the initial public offering price. The stock's first trade was at $18.14 at 11:37 a.m. Eastern for 411,595 shares. The IPO was priced at $15 a share, in the middle of the expected range of $14 to $16 a share. The California-based biopharmaceutical company developing treatments for endocrine disorders raised $90.0 million in the IPO, and the pricing valued the company at about $319 million. The stock has pared gains since its open, to be 7.7% above its IPO price in midday trading. Meanwhile, the Renaissance IPO ETF IPO, +1.98% was up 1.9% and the S&P 500 SPX, +0.87% was rising 0.9%."}]}